Glenmark Life Sciences Limited IPO
Glenmark Life Sciences Limited IPO
Incorporated in 2011, Glenmark Life Sciences ipo is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Competitive strengths
- Glenmark Life Sciences Limited IPO Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
- Export products in Europe, Latin America, North America, Japan, and the rest of the world.
- Strong relationship with leading global generic companies.
- Proven track record of strong financial performance.
- High-quality product manufacturing with R&D infrastructure.